Christoph Rader

Christoph Rader

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
LZLizhou Zhang
Lizhou Zhang
CJCody B. Jackson
Cody B. Jackson
HMHuihui Mou
Huihui Mou
AOAmrita Ojha
Amrita Ojha
HPHaiyong Peng
Haiyong Peng
HCHyeryun Choe
Hyeryun Choe
SARS-CoV-2 variants with spike (S)-protein D614G mutations now predominate globally. We therefore compare the properties of the mutated S protein (SG614) with the original (SD614). We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than those with SD614. This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion. Similar results are obtained with virus-like particles produced with SARS-CoV-2 M, N, E, and S proteins. However, D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may increase infectivity by assembling more functional S protein into the virion.

13 June 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MHMichael Hudecek
Michael Hudecek
MLMaria-Teresa Lupo-Stanghellini
Maria-Teresa Lupo-Stanghellini
PKPaula L. Kosasih
Paula L. Kosasih
DSDaniel Sommermeyer
Daniel Sommermeyer
MJMichael C. Jensen
Michael C. Jensen
SRStanley R. Riddell
Stanley R. Riddell
Purpose: The adoptive transfer of T cells modified to express a chimeric antigen receptor (CAR) comprised of an extracellular single-chain antibody (scFV) fragment specific for a tumor cell surface molecule, and linked to an intracellular signaling module, has activity in advanced malignancies. The receptor tyrosine kinase–like orphan receptor 1 (ROR1) is a tumor-associated molecule expressed in prevalent B-lymphoid and epithelial cancers and is absent on normal mature B cells and vital tissues, making it a candidate for CAR T-cell therapy. Experimental Design: We constructed ROR1-CARs from scFVs with different affinities and containing extracellular IgG4-Fc spacer domains of different lengths, and evaluated the ability of T cells expressing each CAR to recognize ROR1+ hematopoietic and epithelial tumors in vitro, and to eliminate human mantle cell lymphoma (MCL) engrafted into immunodeficient mice. Results: ROR1-CARs containing a short “Hinge-only” extracellular spacer conferred superior lysis of ROR1+ tumor cells and induction of T-cell effector functions compared with CARs with long “Hinge-CH2-CH3” spacers. CARs derived from a higher affinity scFV conferred maximum T-cell effector function against primary CLL and ROR1+ epithelial cancer lines in vitro without inducing activation-induced T-cell death. T cells modified with an optimal ROR1-CAR were equivalently effective as CD19-CAR–modified T cells in mediating regression of JeKo-1 MCL in immunodeficient mice. Conclusions: Our results show that customizing spacer design and increasing affinity of ROR1-CARs enhances T-cell effector function and recognition of ROR1+ tumors. T cells modified with an optimized ROR1-CAR have significant antitumor efficacy in a preclinical model in vivo, suggesting they may be useful to treat ROR1+ tumors in clinical applications. Clin Cancer Res; 19(12); 3153–64. ©2013 AACR.

1 February 2015 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
MHMichael Hudecek
Michael Hudecek
DSDaniel Sommermeyer
Daniel Sommermeyer
PKPaula L. Kosasih
Paula L. Kosasih
ASAnne Silva-Benedict
Anne Silva-Benedict
LLLingfeng Liu
Lingfeng Liu
SRStanley R. Riddell
Stanley R. Riddell
The use of synthetic chimeric antigen receptors (CAR) to redirect T cells to recognize tumor provides a powerful new approach to cancer immunotherapy; however, the attributes of CARs that ensure optimal in vivo tumor recognition remain to be defined. Here, we analyze the influence of length and composition of IgG-derived extracellular spacer domains on the function of CARs. Our studies demonstrate that CD19-CARs with a long spacer from IgG4 hinge-CH2-CH3 are functional in vitro but lack antitumor activity in vivo due to interaction between the Fc domain within the spacer and the Fc receptor–bearing myeloid cells, leading to activation-induced T-cell death. We demonstrate that in vivo persistence and antitumor effects of CAR-T cells with a long spacer can be restored by modifying distinct regions in the CH2 domain that are essential for Fc receptor binding. Our studies demonstrate that modifications that abrogate binding to Fc receptors are crucial for CARs in which a long spacer is obligatory for tumor recognition as shown here for a ROR1-specific CAR. These results demonstrate that the length and composition of the extracellular spacer domain that lacks intrinsic signaling function can be decisive in the design of CARs for optimal in vivo activity. Cancer Immunol Res; 3(2); 125–35. ©2014 AACR.

1 March 2019 in Cancer Cell
Verified
Journal Article
Closed access
SSShivani Srivastava
Shivani Srivastava
ASAlexander I. Salter
Alexander I. Salter
DLDenny Liggitt
Denny Liggitt
SYSushma Yechan-Gunja
Sushma Yechan-Gunja
MSMegha Sarvothama
Megha Sarvothama
SRStanley R. Riddell
Stanley R. Riddell

24 December 2020 in Cancer Cell
Verified
Journal Article
Closed access
SSShivani Srivastava
Shivani Srivastava
SFScott N. Furlan
Scott N. Furlan
CJCarla A. Jaeger-Ruckstuhl
Carla A. Jaeger-Ruckstuhl
MSMegha Sarvothama
Megha Sarvothama
CBCarolina Berger
Carolina Berger
SRStanley R. Riddell
Stanley R. Riddell

25 November 2010 in Blood
Verified
Journal Article
Closed access
PDF file
MHMichael Hudecek
Michael Hudecek
TSThomas M. Schmitt
Thomas M. Schmitt
SBSivasubramanian Baskar
Sivasubramanian Baskar
MLMaria Teresa Lupo-Stanghellini
Maria Teresa Lupo-Stanghellini
TNTetsuya Nishida
Tetsuya Nishida
SRStanley R. Riddell
Stanley R. Riddell
Monoclonal antibodies and T cells modified to express chimeric antigen receptors specific for B-cell lineage surface molecules such as CD20 exert antitumor activity in B-cell malignancies, but deplete normal B cells. The receptor tyrosine kinase-like orphan receptor 1 (ROR1) was identified as a highly expressed gene in B-cell chronic lymphocytic leukemia (B-CLL), but not normal B cells, suggesting it may serve as a tumor-specific target for therapy. We analyzed ROR1-expression in normal nonhematopoietic and hematopoietic cells including B-cell precursors, and in hematopoietic malignancies. ROR1 has characteristics of an oncofetal gene and is expressed in undifferentiated embryonic stem cells, B-CLL and mantle cell lymphoma, but not in major adult tissues apart from low levels in adipose tissue and at an early stage of B-cell development. We constructed a ROR1-specific chimeric antigen receptor that when expressed in T cells from healthy donors or CLL patients conferred specific recognition of primary B-CLL and mantle cell lymphoma, including rare drug effluxing chemotherapy resistant tumor cells that have been implicated in maintaining the malignancy, but not mature normal B cells. T-cell therapies targeting ROR1 may be effective in B-CLL and other ROR1-positive tumors. However, the expression of ROR1 on some normal tissues suggests the potential for toxi-city to subsets of normal cells.